This site is intended for healthcare professionals
Abstract digital waveforms in blue and purple
  • Home
  • /
  • Drugs
  • /
  • G
  • /
  • Galantamine
  • /
  • Galantamine GALANTAMINE HYDROBROMIDE 8 mg/1 Zydus Lifesciences Limited
FDA Drug information

Galantamine

Read time: 1 mins
Marketing start date: 23 Dec 2024
...
 

Summary of product characteristics


Effective Time

20221013

Version

7

Spl Product Data Elements

Galantamine Galantamine GALANTAMINE HYDROBROMIDE GALANTAMINE HYPROMELLOSES LACTOSE MONOHYDRATE MAGNESIUM STEARATE PROPYLENE GLYCOL SILICON DIOXIDE TITANIUM DIOXIDE FERRIC OXIDE RED CROSPOVIDONE (15 MPA.S AT 5%) LIGHT PINK ROUND 77;Z Galantamine Galantamine GALANTAMINE HYDROBROMIDE GALANTAMINE CROSPOVIDONE (15 MPA.S AT 5%) FERRIC OXIDE YELLOW HYPROMELLOSES LACTOSE MONOHYDRATE MAGNESIUM STEARATE PROPYLENE GLYCOL SILICON DIOXIDE TITANIUM DIOXIDE OFF-WHITE ROUND 78;Z Galantamine Galantamine GALANTAMINE HYDROBROMIDE GALANTAMINE CROSPOVIDONE (15 MPA.S AT 5%) FERRIC OXIDE YELLOW LACTOSE MONOHYDRATE MAGNESIUM STEARATE PROPYLENE GLYCOL SILICON DIOXIDE TITANIUM DIOXIDE HYPROMELLOSES OFF-WHITE ROUND 79;Z

Application Number

ANDA078898

Brand Name

Galantamine

Generic Name

Galantamine

Product Ndc

65841-756

Product Type

HUMAN PRESCRIPTION DRUG

Route

ORAL

Package Label Principal Display Panel

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL NDC 65841-755-14 in bottle of 60 tablets Galantamine Tablets USP, 4 mg R x only 60 tablets NDC 65841-756-14 in bottle of 60 tablets Galantamine Tablets USP, 8 mg R x only 60 tablets NDC 65841-757-14 in bottle of 60 tablets Galantamine Tablets USP, 12 mg R x only 60 tablets galantamine tablets USP, 4mg galantamine Tablets USP, 8mg galantamine Tablets USP, 12mg

Drug section

CME banner

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Disclaimer

The drug Prescribing Information (PI), including indications, contra-indications, interactions, etc, has been developed using the U.S. Food & Drug Administration (FDA) as a source (www.fda.gov).

Medthority offers the whole library of PI documents from the FDA. Medthority will not be held liable for explicit or implicit errors, or missing data.

Drugs appearing in this section are approved by the FDA. For regions outside of the United States, this content is for informational purposes only and may not be aligned with local regulatory approvals or guidance.